Labcorp Tops Q2 Estimates, Lifts Full-Year Outlook, and Boosts Buyback by $1B
LH sits 26% above its 52-week low of $244.52.
Summary
Labcorp posted Q2 2026 revenue of $3.73 billion and adjusted EPS of $4.99, both above consensus, and raised full-year guidance. The board also approved a $1.0 billion increase in share repurchase authorization, bringing the total remaining to $1.4 billion.
Key Events · Earnings and Guidance · LH
-
Q2 Revenue and EPS Beat
Revenue reached $3.73 billion, up 5.8% year-over-year, while adjusted EPS of $4.99 rose 14.9%, fueled by organic growth and margin expansion across both Diagnostics and Biopharma segments.
-
Raised Full-Year Guidance
Reflecting a strong first half and an upbeat outlook, management lifted 2026 adjusted EPS guidance to $18.10–$18.55 (midpoint up $0.30) and revenue growth guidance to 5.4%–6.3% (midpoint up 30 bps).
-
$1.0B Buyback Authorization Increase
The board approved a $1.0 billion increase in share repurchase authorization, bringing the total remaining to $1.4 billion. In Q2 alone, the company repurchased $353.8 million of stock.
-
Debt Reduction and Acquisitions
Labcorp retired $500 million in senior notes in June and completed acquisitions of Parkview Health outreach lab services and Tribal Diagnostics, deploying $225.7 million in M&A during the quarter.
Analysis · LH · Industrial Applications And Services
A strong second quarter saw revenue climb 6% and adjusted EPS jump 15%, comfortably ahead of expectations. The raised full-year revenue and EPS guidance signals management's conviction in sustained momentum. Notably, the $1.0 billion increase in share repurchase authorization—lifting the total to $1.4 billion—represents a substantial capital return commitment that underscores management's view of the stock's value. With $353.8 million in buybacks executed during the quarter and $500 million in debt retired, the capital allocation actions are decidedly shareholder-friendly and support the stock near its 52-week high.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.6% of the 1805 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LH was trading at $307.05 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $25.2B. The 52-week trading range was $244.52 to $315.77. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.